Literature DB >> 3113596

Measles in children who have malignant disease.

J Kernahan, J McQuillin, A W Craft.   

Abstract

A review study examined the clinical course of measles diagnosed in children being treated for malignant disease in Newcastle upon Tyne during 1973-86. Of the 17 cases diagnosed, five were fatal. Factors associated with a favourable outcome were a typical rash and Koplik's spots, which were accompanied by a detectable serum antibody response and the disappearance of measles giant cells from nasopharyngeal secretions. Pneumonitis severe enough to require assisted ventilation was invariably fatal. Pneumonitis and encephalitis were the main complications. Treatment included immunoglobulin, interferon, and ribavirin, but none could clearly be shown to be effective. The comparatively low mortality in this series may have been due to the extensive use of the fluorescent antibody technique in Newcastle during the study period and therefore detection of less severe cases as compared with other reports.

Entities:  

Mesh:

Year:  1987        PMID: 3113596      PMCID: PMC1246899          DOI: 10.1136/bmj.295.6589.15

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  20 in total

1.  Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash.

Authors:  J F ENDERS; K McCARTHY; A MITUS; W J CHEATHAM
Journal:  N Engl J Med       Date:  1959-10-29       Impact factor: 91.245

2.  Application of immunofluorescence to a study of measles.

Authors:  J Mcquillin; T M Bell; P S Gardner; P S Downham
Journal:  Arch Dis Child       Date:  1976-06       Impact factor: 3.791

3.  Letter: Atypical measles encephalitis in leukaemic children in remission.

Authors:  D Smyth; J H Tripp; E M Brett; W C Marshall; J Almeida; A D Dayan; J C Coleman; R Dayton
Journal:  Lancet       Date:  1976-09-11       Impact factor: 79.321

4.  Measles eradication policies.

Authors:  N D Noah
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-03

5.  Progress in measles elimination.

Authors:  A R Hinman; D L Eddins; C D Kirby; W A Orenstein; R H Bernier; P M Turner; A B Bloch
Journal:  JAMA       Date:  1982-03-19       Impact factor: 56.272

6.  Development of antiviral levels of ribavirin in serum and urine of orally treated rats.

Authors:  D F Smee; R W Sidwell; B B Barnett; R S Spendlove; R P Sharma
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

7.  Measles mortality. Analysis of the primary cause of death.

Authors:  R M Barkin
Journal:  Am J Dis Child       Date:  1975-03

8.  Directly transmitted infections diseases: control by vaccination.

Authors:  R M Anderson; R M May
Journal:  Science       Date:  1982-02-26       Impact factor: 47.728

9.  Application of live attenuated measles and mumps vaccines in children with acute leukemia.

Authors:  S Torigoe; S Hirai; K Oitani; M Ito; T Ihara; T Iwasa; H Kamiya; M Sakurai; S Ueda; K Yamanishi
Journal:  Biken J       Date:  1981-12

10.  Serious infections during continuing treatment of acute lymphoblastic leukaemia.

Authors:  J Ninane; J M Chessells
Journal:  Arch Dis Child       Date:  1981-11       Impact factor: 3.791

View more
  10 in total

1.  Critical appraisal of published research: introductory guidelines.

Authors:  F G Fowkes; P M Fulton
Journal:  BMJ       Date:  1991-05-11

2.  Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.

Authors:  P R Wyde; D K Moore-Poveda; E De Clercq; J Neyts; A Matsuda; N Minakawa; E Guzman; B E Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  Immunisation for the immunosuppressed child.

Authors:  A G Campbell
Journal:  Arch Dis Child       Date:  1988-02       Impact factor: 3.791

4.  Comparison of different methods and cell lines for isolating measles virus.

Authors:  D N Forthal; J Blanding; S Aarnaes; E M Peterson; L M de la Maza; J G Tilles
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

5.  CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge.

Authors:  M G von Herrath; M Yokoyama; J Dockter; M B Oldstone; J L Whitton
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles.

Authors:  Assan Jaye; Carla A Herberts; Sabelle Jallow; Sowsan Atabani; Michel R Klein; Peter Hoogerhout; Michael Kidd; Cécile A C M van Els; Hilton C Whittle
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 7.  Practical review of immunizations in adult patients with cancer.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Hum Vaccin Immunother       Date:  2015-06-25       Impact factor: 3.452

8.  Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia.

Authors:  I Hughes; M E Jenney; R W Newton; D J Morris; P E Klapper
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 9.  Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease.

Authors:  Shintaro Sagami; Taku Kobayashi; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2018-07-17

Review 10.  Syncytia Formation in Oncolytic Virotherapy.

Authors:  Chase Burton; Eric Bartee
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.